Clinical Advances in Breast Cancer

This Disease Education Center is intended to share with our readers expert opinion and clinical advances in the treatment and management of breast cancer.

Visit the Breast Cancer Video Library for the latest news from key physician opinion leaders.

FDA Advisory Committee Votes to Maintain Approval of Atezolizumab for TNBC

FDA Advisory Committee Votes to Maintain Approval of Atezolizumab for TNBC

The FDA Oncologic Drugs Advisory Committee (ODAC) voted 7-2 in favor of maintaining the accelerated approval of atezolizumab in combination with chemotherapy for the treatment of unresectable locally advanced or metastatic PD-L1 positive triple negative breast cancer...

 
Real-World Data Confirms Benefit of Pertuzumab, Trastuzumab, Docetaxel for ERBB2-Positive MBC

Real-World Data Confirms Benefit of Pertuzumab, Trastuzumab, Docetaxel for ERBB2-Positive MBC

Long-term data upheld early clinical trial results regarding the efficacy of pertuzumab, trastuzumab, and docetaxel in ERBB2+ metastatic breast cancer...

 
Adjuvant Palbociclib Offers No Benefit to Patients With Early Breast Cancer When Added to Endocrine Therapy

Adjuvant Palbociclib Offers No Benefit to Patients With Early Breast Cancer When Added to Endocrine Therapy

The addition of palbociclib to a 2-year course of adjuvant endocrine therapy did not meaningfully improve invasive disease-free survival (DFS) over endocrine therapy alone in patients with early-stage breast cancer...
Margetuximab Outperforms Trastuzumab in Advanced HER2-Positive Breast Cancer

Margetuximab Outperforms Trastuzumab in Advanced HER2-Positive Breast Cancer

Margetuximab appears to be more effective than trastuzumab, each with chemotherapy, in women with pretreated ERBB2 (formerly HER2)-positive advanced breast cancer, which remains largely incurable, according to initial results of the SOPHIA trial...

Breast Cancer Overtakes Lung As Most Common Cancer-WHO

Breast Cancer Overtakes Lung As Most Common Cancer-WHO

Breast cancer has overtaken lung cancer as the most common form of the disease, accounting for nearly 12% of new cases each year worldwide...

Loading...

Featured Video

Emerging New Standard of Care for HER2 Breast Cancer

Emerging New Standard of Care for HER2 Breast Cancer

Stephen Malamud, MD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, explains the differences in efficacy for various CDK drugs.

© 2021 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information